Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
betahistine + ginkgo biloba
- Development stage
- Unknown
- Lead developer
- Insud Pharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Stablanz is a combination pharmaceutical product developed by Ordain Health Care (a division of Exeltis) primarily indicated for the treatment of vertigo and Meniere's disease. It consists of betahistine, a histamine analogue, and Ginkgo biloba extract. Betahistine acts as a potent histamine H3 receptor antagonist and a weak H1 receptor agonist, which facilitates vasodilation in the inner ear and improves microcirculation, thereby reducing the frequency and intensity of vertigo episodes. Ginkgo biloba extract provides complementary effects by enhancing peripheral and cerebral blood flow through its antioxidant properties and inhibition of platelet-activating factor (PAF). The combination is marketed in India as a therapeutic option for managing vestibular disorders and associated symptoms such as tinnitus and hearing loss.
- Brand names
- Stablanz
- Other names
- betahistine dihydrochloride + ginkgo biloba extract
02
Targets
HRH1 (Histamine H1 Receptor)HRH3 (Histamine Receptor H3)PTAFR (Platelet-activating factor receptor)
Beyond the preview
Go deeper on betahistine + ginkgo biloba.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on betahistine + ginkgo biloba.